Top

Published in:

Open Access 01-12-2024 | Acute Myeloid Leukemia | Correspondence

Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting

Authors: Guangcai Zhong, Ran Kong, Shi Feng, Cong Wang, Qingbo Hao, Weilin Xie, Xiangxiang Zhou

Published in: Journal of Hematology & Oncology | Issue 1/2024

Abstract

Protein degraders, emerging as a novel class of therapeutic agents, have gained widespread attention due to their advantages. They have several advantages over traditional small molecule inhibitors, including high target selectivity and ability to target “undruggable” targets and overcome inhibitor drug resistance. Tremendous research and development efforts and massive investment have resulted in rapid advancement of protein degrader drug discovery in recent years. Here, we overview the latest clinical and preclinical updates on protein degraders presented at the 2023 ASH Annual Meeting.

Seymour JF, Cheah CY, Parrondo R, Thompson MC, Stevens DA, Lasica M, et al. First results from a phase 1, first-in-human study of the Bruton’s tyrosine kinase (BTK) degrader Bgb-16673 in patients (pts) with relapsed or refractory (R/R) B-Cell malignancies (BGB-16673-101). Blood. 2023;142(Supplement 1):4401. https://doi.org/10.1182/blood-2023-180109.CrossRef

Searle E, Forconi F, Linton K, Danilov A, McKay P, Lewis D, et al. Initial findings from a first-in-human phase 1a/b trial of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader, in patients with Relapsed/Refractory B cell malignancies. Blood. 2023;142(Supplement 1):4473. https://doi.org/10.1182/blood-2023-179508.CrossRef

Danilov A, Tees MT, Patel K, Wierda WG, Patel M, Flinn IW, et al. A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton’s tyrosine kinase (BTK) Dual-targeted protein degrader with Immunomodulatory Activity, in patients with Relapsed/Refractory B cell malignancies. Blood. 2023;142(Supplement 1):4463. https://doi.org/10.1182/blood-2023-179872.CrossRef

Shastri A, Feldman EJ, Starodub AN, Feldman T, Rodriguez CP, Epstein-Peterson ZD, et al. Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, large Granular lymphocytic leukemia, and solid tumors. Blood. 2023;142(Supplement 1):3081. https://doi.org/10.1182/blood-2023-181130.CrossRef

Xie Y, Xing W, Lai W, Tao M, Gu L, Cao M, et al. Discovery of BCL-XL Heterobifunctional Degrader with potentially improved therapeutic window and minimal platelet toxicity for hematological malignancies. Blood. 2023;142(Supplement 1):117. https://doi.org/10.1182/blood-2023-184887.CrossRef

Diaz Rohena D, Peris Cuesta A, Slawin B, Ravikrishnan J, Liu C, Williams C, et al. Enriched signalling pathways in Venetoclax-relapsed chronic lymphocytic leukemia (CLL) cells and targeting using a Protac-based Bcl-2/Bcl-Xl degrader. Blood. 2023;142(Supplement 1):4195. https://doi.org/10.1182/blood-2023-188250.CrossRef

WANG Z, Zhang Q, Skwarska A, Ramage CL, Zheng G, Gritsman K, et al. Targeting BCL-XL with a novel VHL-Based BCL-XL Degrader DT-2216 in Pre-clinical JAK2-Mutant AML Post-MPN models. Blood. 2023;142(Supplement 1):4154. https://doi.org/10.1182/blood-2023-178813.CrossRef

Furukawa K, Shimada K, Esaki M, Tanaka K, Yamamoto K, Mori K, et al. Development and efficacy of a Novel Bromodomain and Extraterminal Domain Degrader K-256 in MYC/BCL2-Related lymphoma. Blood. 2023;142(Supplement 1):5008. https://doi.org/10.1182/blood-2023-179334.CrossRef

Chakraborty S, Morganti C, Dey J, Zhang H, Aluri S, Gitego N, et al. A STAT3 degrader demonstrates pre-clinical efficacy in Venetoclax resistant Acute Myeloid Leukemia. Blood. 2023;142(Supplement 1):2787. https://doi.org/10.1182/blood-2023-186947.CrossRef

10.

Chiu H, Zhao J, Ortiz Estevez M, Hagner PR, Gandhi AK. Mezigdomide reverses T-Cell exhaustion through Degradation of Aiolos/Ikaros and Reinvigoration of Cytokine Production pathways. Blood. 2023;142(Supplement 1):335. https://doi.org/10.1182/blood-2023-189445.CrossRef

11.

Kim B-R, Kang H, Kim Y-J, Son H, Park J, Park Y, et al. Anti-leukemic effects of CK1α degrader as Monotherapy and in combination with targeted drugs. Blood. 2023;142(Supplement 1):2799. https://doi.org/10.1182/blood-2023-178971.CrossRef

12.

Bekes M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discovery. 2022;21(3):181–200. https://doi.org/10.1038/s41573-021-00371-6.CrossRefPubMed

13.

Casan JM, Seymour JF. Degraders upgraded: the rise of PROTACs in Haematological Malignancies. Blood. 2024. https://doi.org/10.1182/blood.2023022993.CrossRefPubMed

Title: Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting
Authors: Guangcai Zhong
Ran Kong
Shi Feng
Cong Wang
Qingbo Hao
Weilin Xie
Xiangxiang Zhou
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Published in: Journal of Hematology & Oncology / Issue 1/2024
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-024-01533-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model

Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening

Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting

Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis

Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions

cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer